Correction: Donanemab: First Approval

被引：0

|

作者：

Connie Kang ^{[1
]}

机构：

[1] Springer Nature,

来源：

Drugs | 2024年 / 84卷 / 10期

关键词：

D O I：

10.1007/s40265-024-02103-7

中图分类号：

学科分类号：

摘要：

引用

下载

收藏

页码：1335 / 1335

相关论文

共 50 条

[41] Correction: Elafibranor: First Approval
Hannah A. Blair
Drugs, 2024, 84 (9) : 1165 - 1165
[42] Correction to: Tralokinumab: First Approval
Sean Duggan
Drugs, 2021, 81 (15) : 1813 - 1813
[43] Correction to: Darinaparsin: First Approval
James E. Frampton
Drugs, 2022, 82 (16) : 1611 - 1611
[44] Correction to: Lonafarnib: First Approval
Sohita Dhillon
Drugs, 2021, 81 (5) : 619 - 619
[45] Correction to: Sotorasib: First Approval
Hannah A. Blair
Drugs, 2021, 81 (16) : 1947 - 1947
[46] Correction to: Mavacamten: First Approval
Susan J. Keam
Drugs, 2022, 82 (11) : 1235 - 1235
[47] Correction to: Tralokinumab: First Approval
Sean Duggan
Drugs, 2021, 81 (15) : 1811 - 1811
[48] Correction to: Inclisiran: First Approval
Yvette N. Lamb
Drugs, 2021, 81 (9) : 1129 - 1129
[49] Correction to: Decitabine/Cedazuridine: First Approval
Sohita Dhillon
Drugs, 2021, 81 (1) : 179 - 179
[50] Correction to: Camrelizumab: First Global Approval
Anthony Markham
Susan J. Keam
Drugs, 2019, 79 (13) : 1497 - 1497

← 1 2 3 4 5 →